In the claims:

1. (Currently amended) An isolated antibody or functional fragment thereof which binds with and neutralises human NOGO-A wherein said antibody or functional fragment thereof comprises each of the following CDRs:

~~Light chain CDRs set forth in SEQ ID NOs: 1, 2, and 3 and~~

~~Heavy chain CDRs set forth in SEQ ID NOs: 4, 5, and 6~~

CDRL1 as set forth in SEQ ID NO: 1;

CDRL2 as set forth in SEQ ID NO: 2;

CDRL3 as set forth in SEQ ID NO: 3;

CDRH1 as set forth in SEQ ID NO: 4;

CDRH2 as set forth in SEQ ID NO: 5; and

CDRH3 as set forth in SEQ ID NO: 6 or an analog of ~~any~~ CDRH3 wherein the amino acid sequence of ~~said~~ CDRH3 is modified by one amino acid.

2. (Previously presented) An isolated antibody according to claim 1 which binds to SEQ ID NO: 87.

3. (Cancelled)

4. (Withdrawn) An antibody according to claim 2 which binds to a region of human NOGO-A between amino acids 686 to 785

5. (Currently amended) An isolated antibody according to claim 1 wherein CDRH3 is as set forth in SEQ ID NO: 6 ~~which comprises each of the following CDRs:~~

~~Light chain CDRs set forth in SEQ ID NOs: 1, 2, and 3 and~~

~~Heavy chain CDRs set forth in SEQ ID NOs: 4, 5, and 6~~.

6. (Withdrawn) An antibody according to claim 1 which comprises each of the following CDRs:

Light chain CDRs: SEQ.I.D.NO:7, 8 and 9

Heavy chain CDRs: SEQ.I.D.NO:10, 11 and 12.

7. (Withdrawn) An antibody according to claim 1 which comprises each of the following CDRs:

Light chain CDRs:SEQ.I.D.NO:13, 14 and 15;

Heavy chain CDRs: SEQ.I.D.NO:16, 17 and 18.

8. (Cancelled).

9. (Withdrawn) An antibody according to claim 6 which comprises a heavy chain variable domain which comprises each of the CDRs selected from CDRH1, CDRH2 and CDRH3 and a light chain variable domain which comprises one or more CDRs selected from CDRL1, CDRL2 and CDRL3.

10. (Withdrawn) An antibody according to claim 7 which comprises a heavy chain variable domain which comprises each of the CDRs selected from CDRH1, CDRH2 and CDRH3 and a light chain variable domain which comprises one or more CDRs selected from CDRL1, CDRL2 and CDRL3.

11. (Previously presented) An isolated antibody of claim 1 which is a monoclonal antibody.

12. (Previously presented) An isolated antibody of claim 1 which is a humanised or chimeric antibody.

13. (Previously presented) An isolated antibody according to claim 1 wherein the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 37.

14. (Withdrawn) An antibody according to claim 9 wherein the heavy chain variable region comprises the amino acid sequence set forth in SEQ.I.D.NO:38.

15. (Withdrawn) An antibody according to claim 10 wherein the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:39.

16. (Previously presented) An isolated antibody according to claim 1 wherein the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 40.

17. (Withdrawn) An antibody according to claim 9 wherein the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:41.

18. (Withdrawn) An antibody according to claim 10 wherein the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:42.

19. (Previously presented) A pharmaceutical composition comprising an isolated anti-NOGO antibody or functional fragment thereof according to claim 1 together with a pharmaceutically acceptable diluent or carrier.

20. (Withdrawn) The method of treatment or prophylaxis of stroke and other neurological diseases/disorders in a human which comprises administering to said human in need thereof an effective amount of an anti-NOGO antibody, according to claim 1, including altered antibodies or a functional fragment thereof.

21. (Cancelled)

22. (Withdrawn) The method of inhibiting neurodegeneration and/or promoting functional recovery in a human patient suffering, or at risk of developing, a stroke or other neurological disease/disorder which comprises administering to said human in need thereof an effective amount of an anti-NOGO antibody according to claim 1, including altered antibodies or a functional fragment thereof.

23. (Cancelled)

24. (Withdrawn) The method of treating or prophylaxis of stroke or other neurological disease/disorder in a human comprising the step of parenteral administration of a therapeutically effective amount of an anti-NOGO antibody according to claim 1 to said human.

25. (Withdrawn) The method of claim 24 wherein the anti-NOGO antibody is administered intravenously.

26. (Withdrawn) The method of claim 20 wherein the other neurological disease/disorder is selected from the group consisting of;

traumatic brain injury, spinal cord injury, Alzheimer's disease, fronto-temporal dementias (tauopathies), peripheral neuropathy, Parkinson's disease, Huntington's disease and multiple sclerosis.

27. (Withdrawn) The method of promoting axonal sprouting comprising the step of contacting a human axon with an anti-NOGO antibody of claim 1.

28. (Withdrawn) The method of claim 27 wherein the method is in vitro.

29. (Withdrawn) The method of producing an anti-NOGO antibody of claim 1 which specifically binds to and neutralises the activity of human NOGO-A which method comprises the steps of;

(a) providing a first vector encoding a heavy chain of the antibody;

(b) providing a second vector encoding the light chain of the antibody;

(c) co-transfecting a mammalian host cell with said first and second vectors;

(d) culturing the host cell of step (c) in culture media (preferably serum free) under conditions permissive to the secretion of the antibody from said host cell into said culture media;

(e) recovering the secreted antibody of step (d).

30. (Withdrawn) The method of producing an anti-NOGO antibody that competitively inhibits the binding of the antibody of claim 1 which method comprises the steps of;

(a) providing a first vector encoding a heavy chain of the antibody;

(b) providing a second vector encoding the light chain of the antibody;

(c) co-transfecting a mammalian host cell with said first and second vectors;

(d) culturing the host cell of step (c) in culture media (preferably serum free) under conditions permissive to the secretion of the antibody from said host cell into said culture media;

(e) recovering the secreted antibody of step (d).

31. (Withdrawn) The method of producing an intravenously administrable pharmaceutical composition comprising an anti-NOGO antibody which binds to and neutralises the activity of NOGO-A which method comprises the steps of;

(a) providing a first vector encoding a heavy chain of the antibody;

(b) providing a second vector encoding the light chain of the antibody;

(c) introducing (e.g.co-transfecting) said first and second vectors into a mammalian host cell;

(d) culturing the host cell of step (c) in culture media (preferably serum free) wherein said host cell secretes into said culture media an antibody comprising a light and heavy chain;

(e) recovering (and optionally purifying) the secreted antibody of step (d);

(f) incorporating the antibody of step (e) into a intravenously administrable pharmaceutical composition.

32. (Withdrawn) The method of producing an anti-NOGO antibody which binds to human NOGO-A between amino acids 586-785, particularly 586-685 or 686 to 785 and neutralises the activity of said NOGO-A which method comprises the steps of;

(a) providing a first vector encoding a heavy chain of the antibody;

(b) providing a second vector encoding the light chain of the antibody;

(c) introducing (e.g.co-transfecting) said first and second vectors into a mammalian host cell;

(d) culturing the host cell of step (c) in culture media (preferably serum free) wherein said host cell secretes into said culture media an antibody comprising a light and heavy chain;

(e) recovering (and optionally purifying) the secreted antibody of step (d);

33. (Withdrawn) The method according to claim 29 wherein the host cell is selected from the group consisting of; NS0 Sp2/o, CHO, COS, a fibroblast cell such as 3T3, particularly CHO.

34. (Previously presented) An isolated functional fragment of the antibody according to claim 1 which binds to SEQ ID NO: 87.

35. (Cancelled)

36. (Currently amended) An isolated functional fragment of the antibody according to claim 1 ~~which comprises each of the following CDRs:~~

~~Light chain CDRs set forth in SEQ ID NOs: 1, 2, and 3 and~~

~~Heavy chain CDRs set forth in SEQ ID NOs: 4, 5, and 6~~.

37. (New) An isolated functional fragment of the antibody according to claim 5.